Glucagon like Peptide 1 News and Research

RSS

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Eating a meal quickly curtails the release of hormones in the gut and can lead to overeating

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), eating a meal quickly, as compared to slowly, curtails the release of hormones in the gut that induce feelings of being full. The decreased release of these hormones, can often lead to overeating.

4 Nov 2009

Eat slowly to avoid overeating

4 Nov 2009

Roche discloses the results of first Phase III clinical study using Taspoglutide

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research.

29 Oct 2009

Grant awarded to two researchers to study the role of GLP-1 in people at risk for or with diabetes

The American Diabetes Association Research Foundation has selected two scientists, University of Virginia Health System researcher Zhenqi Liu, MD, and Stanford University School of Medicine researcher Gerald Reaven, MD, to receive the American Diabetes Association-Novo Nordisk Clinical/Translational Research Award. This $1.2 million grant program supports efforts to study the effects of intestinal hormones, such as glucagon-like peptide-1 (GLP-1), on obesity and pre-diabetes, two risk factors for type 2 diabetes and cardiovascular disease.

2 Sep 2009

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Bile acids are known to be key regulators of lipid, glucose and overall energy metabolism. Bile acid activation of the G protein-coupled receptor TGR5 has been shown to induce energy expenditure in muscle and brown fat, thereby conferring resistance to weight gain.

2 Sep 2009

NDA for Exenatide once weekly accepted for FDA review

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA).

7 Jul 2009

Why low GI diet makes you feel full

Eating a meal with a low GI (glycaemic index) increases gut hormone production which leads to suppression of appetite and the feeling of fullness.

17 Mar 2009

GlaxoSmithKline starts phase III trial of Syncria (albiglutide) type 2 diabetes medication

GlaxoSmithKline has announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria (albiglutide) in men and women with type 2 diabetes.

18 Feb 2009

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of Byetta (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control.

8 Dec 2008

FDA continues review of Takeda's NDA for Alogliptin

Takeda Pharmaceutical Company Limited has announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S. Food and Drug Administration (FDA) will not be able to complete its review of the alogliptin New Drug Application (NDA) by the Prescription Drug User Fee Act (PDUFA) date of October 27, 2008.

12 Oct 2008

Once a week treatment for type 2 diabetes in the pipeline

Canadian researchers have found that a weekly treatment for type 2 diabetes has proved safe and effective for patients.

8 Sep 2008

Advances in the management of diabetes mellitus

The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.

1 Sep 2008

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.

7 Jan 2008

Alogliptin for type 2 diabetes shows promise in early trial

Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.

26 Jun 2007

How and why weight-reducing surgery sometimes cures diabetes

95% of morbidly obese people – those with a Body Mass Index of over 40 – have Type 2 diabetes, sometimes known as maturity-onset diabetes.

5 Jun 2007

Moderate coffee drinking reduces many risks

Although the American Society for Nutrition's popular ,controversy session, at Experimental Biology 2007 focuses on the health effects of coffee drinking, panel chair Dr. James Coughlin, a toxicology/safety consultant at Coughlin & Associates, says that recent advances in epidemiologic and experimental knowledge have transformed many of the negative health myths about coffee drinking into validated health benefits.

1 May 2007

Natural fibre may help overweight achieve a healthy body weight

It sounds almost too good to be true, but Dr. Raylene Reimer, a researcher at the University of Calgary, Faculty of Kinesiology, believes she may have found an important weapon in the war against obesity.

31 Jan 2007

Melanin concentrating hormone found to be involved with insulin production

A new Joslin Diabetes Center-led study has shown conclusively that a neuropeptide, melanin concentrating hormone (MCH), found in the brain and known for its role in increasing appetite in people, plays a role in the growth of insulin-producing beta cells and the secretion of insulin.

28 Jan 2007

Pine nut oil boosts appetite suppressors

In the face of the growing obesity health challenge, "appetite suppressants are increasingly interesting because they work on the very simple premise of 'What you don't eat now, you won't need to lose later,'" Alexandra Einerhand, director, nutrition and toxicology-Europe at Lipid Nutrition notes.

4 Apr 2006